InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,304.16
(
0.09%
)
Post# of 23979
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

$$$eeker

Send PM Follow Ignore
Followers 29
Posts 2503
Boards Moderated 0
Alias Born 04/09/2010

$$$eeker

Re: None

Monday, 09/28/2015 10:52:27 AM

Monday, September 28, 2015 10:52:27 AM

Post# of 23979
$RXII RXi Pharmaceuticals Granted Patent in China for Lead
Clinical Candidate RXI-109

MARLBOROUGH, Mass.
,
Sept. 28, 2015
/PRNewswire/
--
RXi Pharmaceuticals Corporation
(NASDAQ:
RXII
), a biotechnology
company focused on discovering and developing innovative
therapies primarily in the areas of dermatology and ophthalmology, today
announced that it has
been granted a patent from the State Intellectual Property Office of the People's Republic of China (SIP
O) for the composition and methods of use for RXI-109 and other connective tissue growth factor (CTGF) targeting self -
delivering RNAi compounds (sd-rxRNA®) for the treatment of
fibrotic disorders, including skin fibrosis. The patent is scheduled to expire in 2031.

http://investors.rxipharma.com/Cache/1500076361.PDF?Y=&O=PDF&D=&FID=1500076361&T=&IID=4418218
-
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up